The biological activities of several growth factors/cytokines have been shown to be modulated by binding to molecules of the extracellular matrix. Here, the interactions of PDGF (isoforms AA, BB, and AB), a potent mitogen for mesenchymal cells, with collagens were investigated. All radiolabeled PDGF isoforms specifically interacted with type I, II, III, IV, V, and VI collagens (preferential binding to types III, I, VI, and IV) and their constituent chains, either when immobilized on polystyrene or blotted to nitrocellulose. PDGF-collagen interactions were of medium affinity (K D between 4 and 22 nM) and were inhibited by different soluble collagen chains suggesting a collagenous consensus binding site(s) for the PDGF isoforms investigated. Scatchard analysis revealed molar ratios of up to 3-4 PDGF molecules bound/triple-helical (native) collagen. Biological activity of collagen-bound PDGF was demonstrated by a 1.5-3-fold stimulation of proliferation of human fibroblasts and mouse 3T3 cells. Furthermore, a preferential association of PDGF with the collagenous extracellular matrix of cirrhotic liver could be shown by immunostaining. Our data are in accord with previous studies that localized PDGF in the extracellular matrix of fibroproliferative lesions and suggest that binding of PDGF to collagens may localize and modulate its biological activities.
As a potent mitogen for mesenchymal cells, platelet-derived growth factor (PDGF) 1 plays a major role in conditions characterized by enhanced production and deposition of extracellular matrix such as atherosclerosis and wound healing (1-7), glomerulosclerosis (8, 9) , liver fibrosis (10, 11) , and scleroderma (12) . Attention has focused on the direct effect of PDGF on the cells involved in matrix production, but little is known about the role of the extracellular matrix as a modulator of PDGF action.
There is growing evidence that some extracellular matrix components interact with certain growth factors and cytokines, thus imposing spatial constraints on their biological activities (13) (14) (15) (16) (17) . Examples are the binding of basic fibroblast and of hepatocyte growth factor as well as interleukin-1␣/␤, interleukin-2, interleukin-6, granulocyte-macrophage colony-stimulating factor, interleukin-3, and interferon-␥ to heparin and the heparan sulfate chains of proteoglycans (18 -26) , binding of transforming growth factor ␤1 (TGF␤1) to the core proteins of the proteoglycans decorin and biglycan (16, (27) (28) (29) , to fibronectin (30) , and to latent TGF␤-binding protein (31) . Furthermore, tumor necrosis factor-␣ has been shown to interact with fibronectin (32, 33) . To date, only a few results indicated that collagens, as predominant components of most extracellular matrices, could serve as specific ligands for growth factors. However, two reports indicated that TGF␤1 may bind to type IV collagen, with the bound TGF␤1 serving as a reservoir for the active growth factor (34, 35) .
In previous immunohistological studies, PDGF has been detected in extracellular locations of proliferative lesions of scleroderma (36) and of fetal wounds (37) , suggesting it binds to components of the extracellular matrix. Other studies showed that PDGF AB and BB (but not AA) can interact with the extracellular glycoprotein SPARC/osteonectin (38, 39) , whereas the long form of PDGF AA, with an extended carboxyl terminus of basic amino acids encoded by exon 6, and, to a minor extent, PDGF BB have been found to bind to extracellular heparan sulfate (40 -42) .
In the present study we show that all isoforms of PDGF (PDGF AA, BB, and AB) are retained specifically and with intermediate affinity by several types of collagens, which represent the main extracellular matrix components of advanced fibrotic tissues. Additionally, this collagen-bound PDGF is biologically active. The interaction is inhibited by collagen primary structures, and evidence is provided that a limited number of cross-reactive collagenous epitopes are involved.
EXPERIMENTAL PROCEDURES
Materials--All reagents were either from Merck or Sigma. Polystyrene microtiter plates (Immulon 2 Removawells) were purchased from Dynatech.
Human recombinant PDGF AA ("long form," encompassing 125 amino acids/chain) and PDGF BB were purchased from British Biotechnology and Biomol, respectively. Human recombinant PDGF AB was obtained from Upstate Biotechnology, Lake Placid, NY. Antibodies to PDGF BB were obtained from Upstate Biotechnology (monoclonal antihuman PDGF BB; 05-107) and from Genzyme Corp. (rabbit polyclonal anti-human PDGF BB; ZP215), respectively. Secondary antibodies to rabbit or mouse IgG (M737, Z259) and to the alkaline phosphatase⅐anti-alkaline phosphatase (APAAP) complexes (mouse anti-alkaline phosphatase; 651) were from DAKO, Hamburg, Germany.
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‡ Recipient of a Hermann-and-Lilly-Schilling professorship. To whom correspondence should be addressed. Tel.: 30-8445-4019; Fax: 30-8445-4141. 1 The abbreviations used are: PDGF, platelet-derived growth factor; APAAP, alkaline phosphatase⅐anti-alkaline phosphatase; PBS, phosphate-buffered saline; -ra, reduced and alkylated; TGF␤1, transforming growth factor ␤1; PAGE, polyacrylamide gel electrophoresis; BSA, bovine serum albumin; CB, cyanogen bromide peptide. characterized as pure by SDS-polyacrylamide gel electrophoresis, Western blotting, and radioimmunoassays as described in detail previously (43) (44) (45) (46) (47) (48) . The isolation and purification of native type II collagen (from pepsin digests of human articular cartilage) and of the ␣1 and ␣2 chains of type I collagen were carried out by using standard protocols (48, 49) . Reduction and alkylation (50) of type III, IV, and VI collagens were performed by dissolving the native collagens at 2 mg/ml in 0.5 M TrisHCl, pH 8.6, containing 6 M guanidine, 10 mM EDTA, and 5 mg/ml 2,3-dithiothreitol, followed by a 2-h incubation at 37°C under nitrogen. Reduced collagens were carboxymethylated for 30 min at room temperature after addition of 13.4 mg of iodoacetamide dissolved in 100 l of 0.5 M NaOH. Excess iodoacetamide was quenched with ␤-mercaptoethanol at a final concentration of 1%. Samples were dialyzed against 0.5 M acetic acid and finally lyophilized. Cyanogen bromide (CNBr) peptides were produced by solubilizing 2 mg of single collagen chains in 1 ml of 70% formic acid at room temperature, flushing the tube 10 min with nitrogen, and adding 2 mg of CNBr, followed by a 4-h incubation at 37°C and by lyophilization (51) .
Immobilization of Collagens and Single Collagen Chains-Polystyrene microtiter wells were coated with native triple-helical collagens and collagen chains (at 2-4 g/100 l/well for binding studies and at 50 ng/200 l/well for inhibition experiments) by incubation in 50 mM ammonium bicarbonate, pH 9.6, for 2 h at 37°C, followed by three washes with phosphate-buffered saline (PBS), pH 7.4. Unspecific binding sites were blocked with PBS, containing 0.05% Tween 20 (polyoxyethylene sorbitan monolaureate), overnight at 4°C.
Coating efficiencies were calculated by addition of 5-10 ng/well of collagens that were radiolabeled with 125 I by the chloramine-T method (43, 46, 47) Triple-helical collagens (type I, II, III, IV, V, and VI) were coated at 2 g/100 l, single-chain collagens III, IV, and VI (reduced and alkylated, r/a) and chains ␣1(I) and ␣2(I) at 4 g/100 l, followed by incubation with 1-2 ng of radiolabeled PDGF. Detergent-blocked polystyrene served as control (P). Results are shown as percentage of radioactivity remaining bound to the collagen-coated and detergent-blocked wells after a 2-h incubation and are expressed as mean (Ϯ S.E.) of six (PDGF AA and BB) and three (PDGF AB) independent experiments performed in triplicate. lanes 1 and 7) , ␣2(I) (lanes 2 and 8) , and ␣1(III) (lanes 3 and 9) , and native type IV (lanes 4, 5, 10, and 11) and VI (lanes 6 and 12) collagens were separated by 15% SDS-PAGE and blotted to nitrocellulose. After blocking unspecific binding sites with PBS, 0.3% Tween 20, the blots were either stained with Amido Black (lanes 1-6) or incubated with 100 ng of 125 I-PDGF BB for 2 h, washed, air-dried, and subjected to autoradiography (lanes 7-12). Peptides on lanes 5, 6, 11, and 12 are reduced. Molecular weights of the cyanogen bromide or pepsin-derived collagen fragments are indicated. Note the preferential detection by 125 I-PDGF BB of peptides equivalent to ␣1(I) CB 8 (28 kDa), ␣1(I) CB 6 (20 kDa), a dimeric peptide of ␣1(I) (50 kDa), ␣2(I) CB 3 or CB 5 (31 kDa), ␣2(I) CB 3-5 (62 kDa), ␣1(III) CB9 (24 kDa), and pepsin fragments most probably derived from ␣2(IV) and ␣1(VI).
FIG. 3. Precipitation of
125 I-PDGF BB by fibrillar type I collagen. Various amounts of type I collagen dissolved in acetic acid were incubated with 3-4 ng of radiolabeled PDGF BB (equivalent to 80,000 cpm radiolabeled PDGF BB) and finally precipitated as described under "Experimental Procedures." BSA and pure radiolabeled PDGF BB (ϭ 0 g of ligand) served as controls. Precipitated radioactivity is demonstrated for the various amounts of added type I collagen (open bars) compared to the same amount of BSA (hatched bars).
ing coating efficiencies were almost linear in the range from 50 ng to 4 g/well and as follows for 2 g of collagen/well: collagen type I (30%), II (21%), III (34%), IV (42%), V (43%), VI (40%), ␣1(I) (25%), ␣2(I) (37%), IIIra (reduced and alkylated, 48%), IVra (41%), and VIra (32%).
PDGF Binding Assays-All three PDGF isoforms were radiolabeled with 125 I by using the Bolton-Hunter reagent (DuPont NEN). Labeled PDGF was separated from free iodine over a Sepharose G25 column (PD-10, Pharmacia LK) in PBS, containing 0.05% Tween 20. Incorporated radioactivity was 15,000 -20,000 cpm/ng for PDGF AA, 25,000 -30,000 cpm/ng for PDGF BB, and 10,000 -12,000 cpm/ng for PDGF AB. Protein-bound radioactivity, as determined after precipitation with 10% trichloroacetic acid in the presence of 200 g/200 l bovine serum albumin for 1 h at 4°C, was 90-98% for all three PDGF isoforms. Labeling by the chloramine-T method (IODOBEADS, Pierce) yielded an approximately 3-fold higher incorporation for PDGF AA and AB and, as expected, no significant incorporation for PDGF BB (due to the lack of tyrosine residues). Preparations were checked for purity by 20% SDS-PAGE, followed by autoradiography. Radiolabeled recombinant PDGF BB (10 ng/ml) stimulated proliferation of mouse 3T3 fibroblasts 5-fold and of human foreskin fibroblasts 2-3-fold, confirming that iodination did not destroy its bioactivity (data not shown). Labeled PDGF was stored in aliquots at Ϫ20°C and could be used in binding assays for up to 4 weeks.
For solid phase binding assays, labeled PDGF AA, BB, and AB at 1-2 ng/100 l of binding buffer (PBS containing 0.05% Tween 20) was added to the collagen-coated and detergent-blocked wells. After a 2-h incubation at room temperature, the unbound activity was removed by suction, followed by three washes with PBS, 0.05% Tween 20 and counting of the bound radioactivity in a ␥-counter (MultiPrias, Canberra-Packard, Dreieich, Germany).
For ligand blot experiments, 10 g of CNBr-cleaved peptides from single collagen chains ␣1(I), ␣2(I), and ␣1(III) and type IV and VI collagens were separated by 15% SDS-PAGE and blotted to nitrocellulose. The blots were blocked with PBS, 0.3% Tween 20 overnight at 4°C, washed three times in binding buffer (PBS, 0.05% Tween 20), and incubated with approximately 100 ng of 125 I-labeled PDGF AA, BB, or AB diluted in 20 ml of binding buffer for 2 h at room temperature, followed by three washes with binding buffer before air drying and autoradiography.
For solution binding studies, 1, 2, 10, and 20 g of collagen (type I or VI) or BSA in 100 l of PBS, 0.05% Tween 20 were incubated for 1 h at 37°C, allowing the collagens to form fibrils, followed by addition of 80,000 cpm (3-4 ng) radiolabeled PDGF BB in 100 l of PBS, 0.05% Tween 20 and an additional 2-h incubation at room temperature. Finally the suspensions were centrifuged at 13,000 rpm for 15 min, and the radioactivities of the pellets and supernatants subjected to ␥-counting. These experiments were performed at least three times in triplicate.
Inhibition Experiments-For inhibition experiments, microtiter wells were coated with 50 ng/200 l of the various collagens. Since rapid fibril formation in neutral buffers occurred with solubilized native type I, III, V, and VI collagens as inhibitors, reproducible data could only be obtained with denatured collagen chains, which were isolated as described above. To minimize renaturation and fibril formation, which may also occur to a low extent with denatured collagen chains, probes were heated up to 100°C for 2-3 min immediately before use in experiments. Sequential dilutions of these collagen preparations in 300 l of binding buffer were preincubated with 50 l (1-2 ng) of labeled PDGF in detergent-blocked polypropylene tubes for 2 h at room temperature. Then 150 l of these solutions were added to the collagen-coated wells in duplicate and incubated for an additional 2 h, followed by ␥-counting of bound 125 I-PDGF. Uncoated, detergent-blocked wells served as background controls.
Saturation Binding Studies-For saturation binding experiments, increasing amounts of unlabeled PDGF were mixed with a constant amount of labeled PDGF (1-2 ng, 20,000 -60,000 cpm) in a final volume of 100 l of PBS, 0.05% Tween 20 and incubated in microwells that were coated with 200 -400 ng of native collagens or collagen chains for 2 h at room temperature, followed by three washes and counting of bound 125 I-PDGF as described above. The background at high PDGF concen- trations was reduced by rinsing collagen-coated and uncoated (control) wells three times with PBS (without detergent) and blocking residual unspecific binding sites with 0.5% (w/v) BSA in PBS overnight at 4°C. In order to exclude different binding affinities of radiolabeled versus unlabeled PDGF, binding experiments were also performed using the radiolabeled PDGF isoforms up to a concentration of 50 ng (approximately 750,000 -1,500,000 cpm)/well. The resultant binding curves were superimposable on those obtained with 1 ng of radiolabeled PDGF and increasing amounts of unlabeled growth factor (curves not shown).
Cell Culture Experiments-In order to determine the biological activity of collagen-bound PDGF, cell culture experiments were performed with mouse 3T3 cells (ATCC CCL 92.1) and human foreskin fibroblasts (passage 4 -8). Polystyrene microtiter wells were coated with native triple-helical collagens or the respective collagen chains (both at 1 g/100 l of PBS/well) as described above, washed three times with PBS, incubated with 20 ng of PDGF BB/100 l of PBS for 2 h at room temperature and washed again with PBS. Confluent cells were trypsinized, washed, and seeded at a density of 10 4 cells/100 l of Dulbecco's modified Eagle's medium, containing 0.1% fetal calf serum/ well. After culture for 20 h, proliferation was assessed by addition of 2 Ci of [ 3 H]thymidine (DuPont NEN)/well for an additional 4 h. After freezing and thawing, cellular DNA was collected from the microtiter plates and immobilized onto glass fiber membranes using a cell harvester (Bibby-Dunn). [ 3 H]Thymidine incorporated into DNA was measured by ␤-scintillation counting (LS 1701, Beckman) and cell numbers determined by spectrophotometric quantitation of the activity of hexosaminidase (52) or by counting cell numbers in each well from photographs taken from the center of the wells and representing 70% of the surface area.
Binding and Immunolocalization of PDGF on Human Liver Sections-Cryostat sections (5 m) of human cirrhotic livers (cirrhosis due to alcohol (n ϭ 4) or chronic viral hepatitis (n ϭ 3)) were fixed in acetone for 5 min at 4°C, and air-dried. Sections were preincubated with 60 ng of PDGF BB in 50 l of PBS, 0.05% Tween 20 or in buffer alone. After three washes with PBS, PDGF was immunlocalized using either monoor polyclonal antibodies, followed by incubation with secondary antibodies (alkaline phosphatase-coupled) and the APAAP complex. The incubation and washing steps were performed according to the manufacturer's recommendations (DAKO). Incubations with normal rabbit or mouse IgG instead of the PDGF antibodies served as control.
Statistical Analysis-Binding data are expressed as mean Ϯ S.E. Dissociation constants and the number of binding sites obtained by saturation experiments were analyzed according to the method of Scatchard (53) .
RESULTS

PDGF Binds to Native Type I, II, III, IV, V, and VI Collagens and to Single
Collagen Chains-When a constant amount (1-2 ng) of 125 I-PDGF AA, BB and AB was added to native triplehelical and single-chain type I, II, III, IV, V, and VI collagens immobilized on polystyrene microtiter wells, a high specific binding (expressed as percent of added protein-bound radioactivity) was observed (Fig. 1, A-C) . The relative percentage of growth factor that bound to a particular collagen was similar for all PDGF isoforms, with AA showing a slightly lower binding than BB and AB. 33-44% of added PDGF BB and AB and 29 -36% of PDGF AA bound to type I, III, IV, and VI collagens and their respective chains under these conditions, whereas type II and V collagens (Fig. 1) were less efficient ligands. Unspecific binding to detergent-blocked microtiter wells ranged from 5 to 7% of added 125 I-PDGF (Fig. 1) . In order to visualize and to prove the identity of the collagen-
FIG. 5. Saturation binding of PDGF to immobilized type I collagen and ␣1(I).
Increasing amounts of unlabeled PDGF were mixed with a constant amount (1-2 ng; 25,000 -35,000 cpm) of labeled PDGF AA and BB and incubated for 2 h with immobilized type I collagens and the ␣1(I) chain (coated at 200 and 400 ng/100 l/well, respectively). Bound 125 I-PDGF was determined as described for Fig. 1 , after subtraction of the the radioactivity bound to BSA-blocked wells as unspecific background (ranging between 10% and 15%). The dissociation constants (K D ) of the PDGF-collagen interactions were determined graphically by Scatchard analysis (insets), yielding values around 10
Shown are the results of one (out of three or four) representative experiment(s) performed in triplicate, with PDGF AA (A) and BB (B) bound to type I collagen, and PDGF AA bound to the ␣1(I) chain (C). Dissociation constants obtained for other collagens are listed in Table I . bound growth factor, approximately 50 ng of radiolabeled PDGF AA, BB, and AB were incubated with type I, III, and VI collagens (coated at 2 g/well) as described above. When bound radioactivity was eluted by hot reducing SDS gel sample buffer and analyzed by SDS-PAGE and autoradiography, only bands attributable to the pure PDGF isoforms were identified (data not shown).
In addition, binding of PDGF to all single collagen chains could be demonstrated by carrying out ligand blotting with radiolabeled PDGF isoforms on collagens, collagen chains, and their cyanogen bromide peptides that had been transferred to nitrocellulose after SDS-PAGE. It was remarkable that although the collagen chains bound PDGF similarly well, only a subpopulation of the smaller collagen fragments was identified by ligand blotting, with protein staining demonstrating a comparable transfer of all fragments to nitrocellulose (Fig. 2) . Furthermore, all cyanogen bromide peptides detected of chains ␣1(I), ␣2(I), and ␣1(III) except ␣1(I) CB 8 are derived from the carboxyl-terminal half of the chains.
In order to study if PDGF could bind to collagens that had formed fibrils in vitro, radiolabeled PDGF was added to reconstituted fibrils of type I collagen. With increasing concentrations of type I collagen, up to 40% of added 125 I-PDGF BB specifically coprecipitated with collagen I fibrils, whereas background absorption in the presence of increasing amounts of BSA remained constant (Fig. 3) .
Binding of PDGF to Native Collagens Can Be Blocked by Collagen Chains-Binding of PDGF AA and BB to native type I, II, III, IV, V, and VI collagens immobilized at 50 ng/200 l/well could be inhibited efficiently by the respective denatured collagen chains. Furthermore, PDGF binding to a particular collagen type was blocked by the chains of type I, III, IV, and VI collagens (Fig. 4, A-D) . Thus, the binding of PDGF AA and BB to immobilized native type I, III, IV, and VI collagens could always be inhibited, although to a varying degree, when different combinations of soluble collagen chains and collagenous substrates were used. As an example, soluble denatured type VI collagen at 10 g/150 l blocked binding of PDGF to immobilized type VI collagen by nearly 100% (Fig. 4D) , whereas the soluble ␣2 chain of type I collagen reduced binding by only 78% (Fig. 4C) . Similar results were obtained when the reduced and alkylated chains of type III and IV collagens were used as inhibitors (data not shown). Taken together, the experiments that were performed in a cross-inhibition design suggest: 1) consensus binding sites for PDGF isoforms on type I, III, IV, V, and VI collagens, and 2) these binding sites appear to depend largely on collagen primary structure, since singlechain collagens served as effective inhibitors of the binding of PDGF to native collagens. 
Estimated Affinities of the PDGF-Collagen Interactions-
-4 ϫ 10
Ϫ8 mol/liter, respectively. Binding sites on the ␣1(I) chain coated at 400 ng/well (with a coating efficiency of 25%) were saturated at approximately 100 ng of PDGF AA, equivalent to 3.5 ϫ 10 Ϫ8 mol/liter (Fig. 5C ). Plotting according to the method of Scatchard (Fig. 5, insets) indicated single binding sites for PDGF AA and BB on type I collagen with dissociation constants (K D ) of 1.3 and 2.8 ϫ 10 Ϫ8 M, respectively, and of 0.7 ϫ 10 Ϫ8 M for PDGF AA on ␣1(I). Similar results were obtained for type III, IV, and VI collagens (data not shown). Table I summarizes the results obtained with the PDGF isoforms AA and BB on various native and single-chain collagens. The maximum amount of PDGF bound to type I collagen was estimated to be 7.0 ϫ 10 Ϫ13 mol (20 ng) for PDGF AA and 8.4 ϫ 10 Ϫ13 mol (21 ng) for PDGF BB (Fig. 5, A and B) , and that of PDGF AA bound to ␣1(I) 1.5 ϫ 10 Ϫ13 mol (4.2 ng) (Fig. 5C ). Since these numbers were obtained with approximately 60 ng of immobilized type I collagen and 100 ng of ␣1(I), equivalent to 2.0 ϫ 10 Ϫ13 mol of type I collagen and 1.0 ϫ 10 Ϫ12 mol of ␣1(I), respectively, roughly 3.5 or 4.2 mol of PDGF AA or BB bound to 1 mol of type I collagen in the assay system used, whereas binding to the ␣1(I) chain resulted in much lower molar ratios around 0.2. For the binding of PDGF AA and BB to native and single-chain type III, IV, and VI collagens and ␣2(I), similar molar ratios were obtained (Table I) .
Collagen-bound PDGF BB Stimulates Proliferation of 3T3 Cells and Human Foreskin Fibroblasts-Collagen-bound
PDGF BB stimulated proliferation of mouse 3T3 cells by 2-3-fold when compared to cells grown on a collagen matrix alone. Fig. 6 (A and B) shows the results for PDGF BB that was immobilized on type I collagen or on the ␣(I) chain prior to seeding. Proliferation was assessed by [ 3 H]thymidine incorporation into DNA, and cell numbers were determined by using the hexosaminidase method and direct cell counting. DNA synthesis was also stimulated (to a lower extent) in human foreskin fibroblasts (Fig. 6A) , whereas the cell numbers of human fibroblasts plus or minus PDGF BB were the same after only 24 h of incubation (data not shown).
PDGF BB Is Sequestered by the Fibrous Extracellular Matrix of Cirrhotic Liver-Immunostaining (APAAP) of cryostat sections from cirrhotic livers with mono-and polyclonal antibodies to PDGF resulted in low signals that were preferentially found in sinusoidal and blood vessel walls (data not shown). However, when sections were preincubated with PDGF BB, bound growth factor was exclusively localized in the fibrous extracellular matrix of the fibrotic septa, the periportal extracellular matrix, and to a lower extent in the extracellular matrix of the perisinusoidal space (Fig. 7, A and B) , whereas no staining was observed on sections that were preincubated with PDGF, followed by nonimmune primary IgG (Fig. 7, C and D) . DISCUSSION Our study demonstrates that PDGF binds to immobilized type I, II, III, IV, V, and VI collagens as well as to fibrils of type I collagens reconstituted in vitro. PDGF isoforms AA, BB, and AB interacted preferentially with type I, III, IV, and VI collagens, an interaction that was saturable and could be inhibited by soluble denatured collagen chains. In addition, cross-inhibition experiments with soluble collagen chains suggested consensus binding sites on the collagens investigated. Saturation binding studies yielded dissociation constants around 10 Ϫ8 M for all PDGF isoforms that compare well with a variety of other medium affinity protein-protein interactions (54, 55) .
The collagens and the collagen chains that were used for the binding assays had been purified by ion exchange and/or molecular exclusion chromatography and were of high purity, a precondition necessary to exclude binding to other, potential contaminants. In particular, traces of proteoglycans and glycosaminoglycans, which are known to interact with several growth factors including the long form of PDGF AA (56), could be ruled out since all collagen preparations had been pread- FIG. 7 . PDGF BB is sequestered by the fibrous extracellular matrix of cirrhotic liver. Cryostat sections (magnification, ϫ250) of a cirrhotic liver (alcohol-induced) were preincubated with PDGF BB, followed by immunlocalization (APAAP) of the growth factor with mouse monoclonal (A) and rabbit polyclonal (B) antibodies to PDGF BB as described under "Experimental Procedures." Mouse (C) and rabbit IgG (D) served as controls.
sorbed on DEAE-cellulose under conditions that retain these acidic molecules when collagens are eluted. The long form of PDGF AA comprises 125 amino acids and contains an exon 6-encoded basic sequence, which interacts with heparin and heparan sulfate. A similar sequence is found in the COOHterminal pro-sequence of the PDGF B-chain but not in the short form of the A-chain (56) . For our experiments we used the long form of recombinant PDGF AA and the recombinant "mature" PDGF BB lacking the homologous exon 6 pro-sequence. Therefore, the similar binding pattern of PDGF AA and BB to collagens underlines again that traces of contaminating heparan sulfate do not appear to be involved in the interaction. Furthermore, a 200-fold excess (w/w) of soluble heparin did not alter binding of PDGF AA and BB to the collagens (data not shown). Similarly, purity of the radiolabeled PDGF isoforms was evidenced by SDS-PAGE and autoradiography.
A disadvantage of solid-phase assays is the potential masking or distortion of interactive domains on the collagens due to their interaction with the polystyrene, which may lead to an underestimation of binding sites. For example, the calculation of the stoichiometry of the interaction of PDGF BB with type I collagen yields 1 mol of the native triple-helical collagen binding around 3-4 mol of PDGF, whereas 1 mol of single ␣1(I) chain binds only around 0.2 mol of PDGF (Fig. 5) . Assuming that some interactive domains might be masked, our calculated number of binding sites should be considered as a minimum. Therefore, the finding of more binding sites per chain of triplehelical collagen might be either explained by the lower degree of distortion and epitope masking after coating to polystyrene when native are compared to denatured collagens or by a more favorable spatial arrangement of the binding epitope(s) on the collagen triple helix.
Binding of the PDGF isoforms to collagens was also demonstrated by the ligand blot technique and by precipitation of PDGF by collagen fibrils reconstituted in vitro, supporting the results of the polystyrene microtiter assay. Cross-inhibition experiments showed that different soluble collagen chains were able to inhibit the binding of the PDGF isoforms to coats of a given triple-helical or denatured collagen. This leads us to conclude that the collagenous binding sites for PDGF may be variations of a consensus domain. Again, the effective inhibition of the PDGF interaction with triple-helical collagens by single chains of (denatured) collagens suggests the involvement of collagen primary structure. The high degree of inhibition reached by single collagen chains may be explained by the exposure of the variable, potentially interactive amino acids of the collagens on the surface of the triple helix, while the repetitive, and possibly non-interactive, glycine residues are hidden in the triple-helical core. Since radiolabeled PDGF bound only to a subpopulation of CNBr peptides of different collagen chains after transfer to nitrocellulose, there appears to be only a limited number of collagen primary structures that interact with PDGF. Accordingly, we observed that only between one and three out of 40 -50 peptide fractions derived from HPLC chromatographs of V8 and tryptic digests of single collagen chains (with an average of 15-25 amino acid residues/peptide) were inhibitors of the PDGF-collagen interaction.
2 Consequently, the PDGF-binding domain(s) may be a suitable target for competitive inhibitors of the PDGF interactions with the collagenous extracellular matrix.
We can show further that the biological activity, determined as stimulation of mesenchymal cell proliferation, was maintained when PDGF BB was bound to collagens. In addition, the collagenous interstitial extracellular matrix of cirrhotic liver efficiently and specifically sequestered PDGF BB. Taken together, these findings point to a role of the PDGF-collagen interaction in vivo, e.g. during pathogenesis of organ fibrosis when large amounts of collagen are deposited in the extracellular matrix. However, we cannot exclude binding of PDGF to additional constituents that are associated with the fibrous extracellular matrix in the immunlabeling experiments. The finding that very little immunoreactive PDGF is detected in most normal and fibrotic tissues could be due to a rapid uptake and internalization of deposited PDGF by the high affinity PDGF receptors that display affinity constants 2-3 orders of magnitude higher than the PDGF-collagen interactions. Collagens might thus only serve as a short term store that prevents rapid diffusion into the interstitial fluid or the blood stream. "Stored" PDGF may hereby perpetuate mesenchymal cell proliferation and subsequent matrix accumulation, even in the absence of significant inflammation, as observed in cases of advanced glomerulosclerosis and liver fibrosis/cirrhosis (11, 57) . Thus, previous reports of PDGF AA interacting with heparin or heparan sulfate proteoglycan (40, 41) and of PDGF BB and AB binding to the glycoprotein SPARC (38) , extracellular matrix components that are expressed during tissue remodeling and in active fibrotic lesions, are complemented by our finding of an interaction of all PDGF isoforms with collagens as the predominant constituents in advanced fibrotic tissues.
In conclusion, the preferential and short-lived binding of PDGF to interstitial collagens may be an important regulatory mechanism in the physiology and pathophysiology of wound healing and organ fibrosis. Since the binding of PDGF seems to be mediated and effectively inhibited by collagenous consensus sequences, further work is aimed at the use of specific inhibitory peptides for a lesion-targeted approach to modulate these conditions.
